Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Link opens in a new tab
Search content at Bar-Ilan University
Home
Researchers
Organisations
Research output
Prizes
Student theses
Courses
Activities
Projects
Press/Media
Datasets
Equipment
Emicizumab prophylaxis in infants: Single-centre experience
Sarina Levy-Mendelovich
, Noa Greenberg-kushnir
, Ivan Budnik
, Assaf Arie Barg
, Omri Cohen
, Einat Avishai
, Tami Barazani-Brutman
, Tami Livnat
, Gili Kenet
Sheba Medical Center at Tel Hashomer
Tel Aviv University
University of Iowa
University of Insubria
Research output
:
Contribution to journal
›
Article
›
peer-review
9
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emicizumab prophylaxis in infants: Single-centre experience'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Single-center Experience
100%
Emicizumab
100%
Demographic Variables
16%
Clinical Variables
16%
Treatment Outcome
16%
Surgical Outcomes
16%
Steady State
16%
Longitudinal Follow-up
16%
Pediatric
16%
Single Center
16%
Treatment Strategy
16%
Bleeding Events
16%
Laboratory Parameters
16%
Intracranial Hemorrhage
16%
Peak Height
16%
Loading Time
16%
Spontaneous Bleeding
16%
Hemophilia
16%
Thrombin Generation
16%
Open Arm
16%
FVIII Inhibitors
16%
Severe Haemophilia A
16%
Haemophilia Care
16%
Event Outcomes
16%
Endogenous Thrombin Potential
16%
Personalized Care
16%
Nonreplacement Therapy
16%
FVIII Prophylaxis
16%
Bleeding Prevention
16%
Factor Replacement Therapy
16%
Continuous Evaluation
16%
Medicine and Dentistry
Emicizumab
100%
Thrombin
33%
Substitution Therapy
33%
Haemophilia A
33%
Bleeding
16%
Pediatrics
16%
Steady State
16%
Prospective Study
16%
Arm
16%
Cerebral Hemorrhage
16%
Haemophilia
16%
Pharmacology, Toxicology and Pharmaceutical Science
Emicizumab
100%
Replacement Therapy
33%
Thrombin
33%
Haemophilia A
33%
Prospective Study
16%
Bleeding
16%
Brain Hemorrhage
16%
Haemophilia
16%
Immunology and Microbiology
Emicizumab
100%
Thrombin
33%
Steady State
16%
Arm
16%